Author Disclosure Information

Total Page:16

File Type:pdf, Size:1020Kb

Author Disclosure Information ABSTRACT AUTHOR DISCLOSURE INFORMATION All presenters/authors are required to disclose to the program audience any financial relationships related to the subject matter of this program� The intent of this disclosure is not to prevent a presenter or author from being involved in the activity, but rather to provide participants with information on which they may make their own judgments� AUTHOR RELATIONSHIP/COMPANY AUTHOR RELATIONSHIP/COMPANY Aagren, Mark ���������������������������������������� Employee: Novo Nordisk A/S� Acosta, Nicholas K� ������������������������������ Disclosed no conflict of interest. Aakhus, Svend��������������������������������������� Disclosed no conflict of interest. Adachi, Yusuke �������������������������������������� Disclosed no conflict of interest. Aanstoot, Henk-Jan ������������������������������ Advisory Panel: Medtronic MiniMed, Inc�, Novo Nordisk; Adam, Daniel����������������������������������������� Disclosed no conflict of interest. Employee: Diabeter; Research Support: Dexcom, Inc�, Adam, Tanja ������������������������������������������ Disclosed no conflict of interest. DiabetesFonds Nederland, Juvenile Diabetes Research Adam, Terrence ������������������������������������� Disclosed no conflict of interest. Foundation, Roche Diabetes Care� Adamidis, Adam ������������������������������������ Disclosed no conflict of interest. Abadia, Beatriz �������������������������������������� Disclosed no conflict of interest. Adamo, Michela ������������������������������������ Disclosed no conflict of interest. Abbas, Malak ���������������������������������������� Disclosed no conflict of interest. Adams, Alyssa��������������������������������������� Disclosed no conflict of interest. Abbas, Minan ���������������������������������������� Disclosed no conflict of interest. Adams, Andrew C� ������������������������������� Disclosed no conflict of interest. Abbasi, Fahim���������������������������������������� Research Support: Quest Diagnostics Incorporated� Adams, Ashley �������������������������������������� Disclosed no conflict of interest. Abbott, Akshar B� ��������������������������������� Disclosed no conflict of interest. Adams, John ����������������������������������������� Disclosed no conflict of interest. Abbott, Scott ����������������������������������������� Employee: Valeritas, Inc�; Stock/Shareholder: Valeritas, Inc� Adams, Rebecca N� ������������������������������ Disclosed no conflict of interest. Abbott, Shaun ��������������������������������������� Employee: ProMetic BioSciences Inc�; Stock/Shareholder: Adams, Sean H� ������������������������������������ Disclosed no conflict of interest. ProMetic Life Sciences Inc� Adams-Huet, Beverley �������������������������� Disclosed no conflict of interest. Abd El-Hafez, Hala �������������������������������� Disclosed no conflict of interest. Adamski, Jerzy �������������������������������������� Disclosed no conflict of interest. Abdelhadi, Jenna ���������������������������������� Disclosed no conflict of interest. Adamson, Karen ������������������������������������ Disclosed no conflict of interest. Abdelhay, Osama ���������������������������������� Disclosed no conflict of interest. Adas, Mine �������������������������������������������� Disclosed no conflict of interest. Abdella, Nabilla ������������������������������������ Disclosed no conflict of interest. Ader, Marilyn ����������������������������������������� Research Support: AstraZeneca� Abdelmalek, Manal ������������������������������� Consultant: TaiwanJ Pharmaceuticals; Research Support: Adeva, Marta ���������������������������������������� Disclosed no conflict of interest. Arisaph Pharmaceuticals, Inc�, Bristol-Myers Squibb Adeyemo, Adebowale A� ��������������������� Disclosed no conflict of interest. Company, Galmed, Genfit, Gilead, Immuron, Intercept Adi, Saleh ���������������������������������������������� Disclosed no conflict of interest. Pharmaceuticals, Inc�, National Institute of Diabetes and Adili, Fatemeh ��������������������������������������� Disclosed no conflict of interest. Digestive and Kidney Diseases, NGM Biopharmaceuticals, Adkins, Laura����������������������������������������� Disclosed no conflict of interest. TaiwanJ Pharmaceuticals, Tobira Therapeutics, Inc�; Adlan, Mohamed A� ����������������������������� Disclosed no conflict of interest. Speaker’s Bureau: Alexion Pharmaceuticals� Admassu, Bitiya ������������������������������������ Disclosed no conflict of interest. AUTHOR DISCLOSURE Abderrahmani, Amar ����������������������������� Disclosed no conflict of interest. Admon, Gil��������������������������������������������� Disclosed no conflict of interest. Abdo, Kaitlyn I� ������������������������������������� Disclosed no conflict of interest. Adrian, Charlotte L� ������������������������������ Employee: Novo Nordisk A/S; Stock/Shareholder: Novo Abdoli, Samereh������������������������������������ Disclosed no conflict of interest. Nordisk A/S� Abdul-Ghani, Muhammad ��������������������� Disclosed no conflict of interest. Advani, Andrew������������������������������������� Advisory Panel: Abbott, Novo Nordisk A/S; Research Support: Abdullah, Mohamed������������������������������ Disclosed no conflict of interest. AstraZeneca, Boehringer Ingelheim GmbH� Abdulreda, Midhat H� ��������������������������� Disclosed no conflict of interest. Agarwal, Neera ������������������������������������� Disclosed no conflict of interest. Abdulvapova, Zera �������������������������������� Disclosed no conflict of interest. Agarwal, Parul��������������������������������������� Disclosed no conflict of interest. Abdurrachim, Desiree ��������������������������� Research Support: Boehringer Ingelheim GmbH� Agarwal, Prasoon ���������������������������������� Disclosed no conflict of interest. Abe, Masanori��������������������������������������� Disclosed no conflict of interest. Agarwal, Rajiv ��������������������������������������� Advisory Panel: Akebia, Relypsa; Board Member: Akebia, Abe, Megumi����������������������������������������� Disclosed no conflict of interest. AstraZeneca, Bayer, Boehringer Ingelheim, Johnson & Abe, Sunao �������������������������������������������� Employee: Marine Products Kimuraya Co, Ltd� Johnson Services, Inc�, Opko, Relypsa; Employee: Indiana Abed, Ellie ��������������������������������������������� Disclosed no conflict of interest. University; Other Relationship: UpToDate; Research Abel, Brent �������������������������������������������� Disclosed no conflict of interest. Support: National Institutes of Health, United States Abel, E� Dale������������������������������������������ Disclosed no conflict of interest. Department of Veterans Affairs� Abera, Mubarek ������������������������������������ Disclosed no conflict of interest. Agarwal, Shivani ����������������������������������� Disclosed no conflict of interest. Aberer, Felix ������������������������������������������ Disclosed no conflict of interest. Aggarwal, Naresh ��������������������������������� Disclosed no conflict of interest. Abettan, Charlotte��������������������������������� Disclosed no conflict of interest. Aghajan, Yasmin ����������������������������������� Disclosed no conflict of interest. Abi Khalil, Charbel �������������������������������� Disclosed no conflict of interest. Agner, Bue F� Ross ��������������������������������� Employee: Novo Nordisk A/S� Abiru, Norio ������������������������������������������� Disclosed no conflict of interest. Agrawal, Prabhat ���������������������������������� Disclosed no conflict of interest. Abitbol, Alexander �������������������������������� Consultant: AstraZeneca, Janssen Pharmaceuticals, Inc�, Merck Agrawal, Pratik�������������������������������������� Disclosed no conflict of interest. Canada Inc�, Novo Nordisk Inc�, Valeant Pharmaceuticals Agrawal, Rahul�������������������������������������� Disclosed no conflict of interest. International, Inc�; Other Relationship: AstraZeneca, Agrawal, Veena R� ������������������������������� Disclosed no conflict of interest. Boehringer Ingelheim Pharmaceuticals, Inc�, Eli Lilly Canada Aguayo-Armendariz, Josefina ��������������� Disclosed no conflict of interest. Inc�, Lexicon Pharmaceuticals, Inc�, Merck Canada Inc�, Aguilar García, Alberto ������������������������� Disclosed no conflict of interest. Sanofi Canada; Research Support: JA DaSeve Research Aguirre-Quispe, Wilfor �������������������������� Disclosed no conflict of interest. Grant, Juvenile Diabetes Research Foundation� Agus, Michael S� ���������������������������������� Disclosed no conflict of interest. Able, Ashley A� ������������������������������������� Disclosed no conflict of interest. Agustin, Bianca I� ��������������������������������� Disclosed no conflict of interest. Abo Zaid, Wisam����������������������������������� Disclosed no conflict of interest. Agwu, Chizo Juliana ����������������������������� Disclosed no conflict of interest. Abonyi-Tóth, Zsolt ��������������������������������� Disclosed no conflict of interest. Ahad, Abdul������������������������������������������� Disclosed no conflict of interest. Abraham, Mona A� ������������������������������� Disclosed no conflict of interest. Aharon, Shani���������������������������������������� Employee: PatientsLikeMe; Research Support: AstraZeneca� Abrahamsen, Trine �������������������������������� Employee: Novo Nordisk A/S; Stock/Shareholder: Novo Ahlén, Elsa �������������������������������������������� Disclosed no conflict of interest. Nordisk A/S�
Recommended publications
  • From the Academy
    FROM THE ACADEMY Joint American Academy of DermatologyeNational Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy Craig A. Elmets, MD (Co-Chair),a HenryW.Lim,MD,b Benjamin Stoff, MD, MA,c Cody Connor, MD,a Kelly M. Cordoro, MD,d Mark Lebwohl, MD,e AprilW.Armstrong,MD,MPH,f Dawn M. R. Davis, MD,g Boni E. Elewski, MD,a Joel M. Gelfand, MD, MSCE,h Kenneth B. Gordon, MD,i AliceB.Gottlieb,MD,PhD,j Daniel H. Kaplan, MD, PhD,k Arthur Kavanaugh, MD,l Matthew Kiselica, BA/BS,m Dario Kivelevitch, MD,n Neil J. Korman, MD, PhD,o Daniela Kroshinsky, MD, MPH,p Craig L. Leonardi, MD,q Jason Lichten, MD,m NehalN.Mehta,MD,MSCE,r Amy S. Paller, MD,s Sylvia L. Parra, MD,t Arun L. Pathy, MD,u Elizabeth A. Farley Prater, MD,v Reena N. Rupani, MD,e Michael Siegel, PhD,m BruceE.Strober,MD,PhD,w,x Emily B. Wong, MD,y Jashin J. Wu, MD,z Vidhya Hariharan, PhD,aa and Alan Menter, MD (Co-Chair)n Birmingham, Alabama; Detroit, Michigan; Atlanta, Georgia; San Francisco, Los Angeles, San Diego, and Irvine, California; New York, New York; Rochester, Minnesota; Philadelphia and Pittsburgh, Pennsylva- nia; Milwaukee, Wisconsin; Portland, Oregon; Dallas and San Antonio, Texas; Cleveland, Ohio; Boston, Massachusetts; St. Louis, Missouri; Bethesda, Maryland; Chicago and Rosemont, Illinois; Sumter, South Carolina; Centennial, Colorado; Oklahoma City, Oklahoma; Farmington, Connecticut; and Waterloo, Ontario, Canada Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world’s population.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Diabetes Close up December Supplement, 2005, No. 53 J&J To
    Diabetes Close Up December supplement, 2005, No. 53 J&J To Buy Animas in Sublime Strategic Play T h e S h o r t e r V e r s i o n From the Editor: J&J’s LifeScan announced December 16 that it intends to buy Animas Corporation for $518 million in cash, or $24.50/share, a 35% premium over Animas’ closing price the 15th. We think this acquisition makes very good strategic sense – essentially, it’s the #1 glucose monitoring company buying the #2 pump player. In many respects, this was a classic J&J deal – Animas is newly profitable this year, the deal is immediately accretive, and it offers J&J an excellent leg up as it enters the pump market. Too, J&J had owned ~10% of Animas for some time. Now, while Animas is #2, it is still far behind leader Medtronic MiniMed, whose new(ish) leader, successful cardiac surgery veteran Bob Guezuraga has really impressed the diabetes community. Smart, ambitious, and seemingly hyper-focused, he appears very serious about taking the business to the next level and leaving success in diabetes as his legacy. What could be better for patients than significant focus industry-wide on better physiologic delivery? As competition heightens, we expect innovation to move faster – all good, from a patient perspective. Details on the acquisition are below – what J&J gets, what Animas gets, and what’s next. What a way to end what’s been a very dynamic year in diabetes … --Kelly L. Close DCU #53, December supplement 2005, J&J Buys Animas in Sublimely Strategic Deal.
    [Show full text]
  • Lifescan Ethicon
    LouiseLouise MehrotraMehrotra ViceVice PresidentPresident InvestorInvestor RelationsRelations ““SafeSafe HarborHarbor”” StatementStatement This presentation may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments. WilliamWilliam C.C. WeldonWeldon ChairmanChairman ofof thethe BoardBoard && ChiefChief ExecutiveExecutive OfficerOfficer TodayToday’’ss AgendaAgenda
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • JJPAF PAH Brochure
    We help financially eligible patients receive prescription medications donated by Johnson & Johnson operating companies. Visit www.JJPAF.org to learn more or call 833-919-3510 (toll free) 308-920-4358 (direct dial) If you don’t have prescription coverage and can’t get access to Johnson & Johnson operating companies’ medications, we may be able to help. The Patient Assistance Program Our free prescription program is available to anyone who meets the requirements listed below: • You have been prescribed a Johnson & Johnson donated medication • You meet the eligibility income requirements for the product(s) • You don’t have any insurance or your medication is not covered – Some patients with Medicare Prescription Drug Coverage (Part D) who cannot afford their medications and who meet certain financial criteria may also be eligible for assistance • You live in the United States or a U.S. territory • You are being treated by a U.S. licensed doctor as an outpatient How the program works About the Foundation Visit us online • The Patient Assistance Program covers five The Johnson & Johnson Patient Assistance Foundation, We invite you to navigate and explore pulmonary arterial hypertension (PAH) Inc. (JJPAF) is an independent, non-profit organization www.JJPAF.org on your computer, tablet, prescription products as well as over that is committed to helping eligible patients without or smart phone. Website features include: 35 other prescription medications insurance coverage receive prescription products • User-friendly navigation donated by Johnson & Johnson operating companies. – The list of currently available PAH • Medication search functionality medications can be found at www.JJPAF.org Last year, we distributed over 580,000 units of • Step-by-step interactive process to check medication, helping more than 95,000 people receive • Once you meet program requirements and are patient eligibility approved, you’ll receive your medications for the medications they need.
    [Show full text]
  • Open PDF File, 175.47 KB, for Top 100 Covered Recipients, Non Hospital
    Top 100 Covered Recipients, Non Hospital, Detail Rank Recipient City State License License Covered Manufacturer Manufacturer Payment Number Total Fullname Type Number Recipient Name ID Categories of Payment ID Events QUADRANT HEALTH BEVERLY MA Clinical 22D2063293 357395 Novartis CC0243 Other 61 $2,251,831.00 STRATEGIES INC Laboratory Pharmaceuticals 1 Total for Covered Recipient : QUADRANT HEALTH STRATEGIES INC $2,251,831.00 BOSTON BOSTON MA Clinical 22D0996308 241308 Celgene CC0109 Grants/ 2 $30,000.00 UNIVERSITY Laboratory Corporation Educational SCHOOL OF Gifts MEDICINE Csl Behring Llc CC0101 Education/ 2 $5,000.00 Training Depuy CC0135 CMEs, third- 2 $26,000.00 Orthopaedics, Inc., party Conferences, or Meetings Other 1 $7,500.00 Dr. Reddy's CC0592 Grants/ 2 $121,820.00 Laboratories, Inc Educational Gifts Janssen Biotech, CC0194 Grants/ 2 $105,000.00 Inc. Educational Gifts Other 1 $1,500.00 Janssen CC0535 CMEs, third- 2 $175,000.00 Pharmaceuticals, party Inc. Conferences, or Meetings Novo Nordisk Inc. CC0006 Grants/ 2 $136,436.00 Educational Gifts Smith & Nephew, CC0402 CMEs, third- 1 $1,000.00 Inc. party Conferences, or Meetings Stryker Corporation CC0290 CMEs, third- 1 $1,000.00 party Conferences, or Meetings Takeda CC0300 CMEs, third- 2 $60,218.00 Pharmaceuticals party Aug 1, 2016 1 8:44:29 AM Top 100 Covered Recipients, Non Hospital, Detail Rank Recipient City State License License Covered Manufacturer Manufacturer Payment Number Total Fullname Type Number Recipient Name ID Categories of Payment ID Events BOSTON BOSTON MA Clinical 22D0996308 241308 America, Inc CC0300 Conferences, or UNIVERSITY Laboratory Meetings SCHOOL OF Grants/ 3 $800,000.00 MEDICINE Educational Gifts Valeant CC0346 CMEs, third- 2 $5,000.00 Pharmaceuticals party North America Conferences, or Meetings W.L.
    [Show full text]
  • Christine Feorino)
    Year-End Appeal 2015 YOUR SUPPORT HELPS PUT YOUTH ON THE RIGHT PATH Somerset Home’s mission is to aunt was not the best choice. provide abused, neglected, homeless, Fortunately however, he knew and runaway youth with housing, he could call Somerset Home for a stable environment, and help. Benji started in the Pathways supportive services to help program earlier this year. Pathways them become self-sufficient. counselors helped him get a steady Self-sufficiency is a key component job, learn how to budget, and find to ensure youth are prepared to live his own place. He is now working and thrive on their own well beyond two jobs – in retail and food service - Somerset Home. Through the and has saved more than $2,000. Pathways independent-living skills program, youth receive the tools and Until last year, Pathways worked knowledge needed for success. One mostly with clients who lived at of those youth is Benji... the Somerset Home residential programs. Since then, the program Benji was a resident at Passages. branched out to serve clients His father was incarcerated and his throughout central New Jersey. mother had substance abuse issues. The expansion has resulted in a As a result, he and his siblings would steady increase in referrals. This Pathways clients receive tools and knowledge to succeed in life. go weeks being neglected until they year, Pathways has served almost were ultimately put in foster care. 60 clients - a tremendous increase After living at Passages for several from previous years. employment, pertinent documents, driver’s licenses, and more. months, he decided to leave and live “I cannot thank Pathways enough for all your services”, said Benji.
    [Show full text]
  • Medtronics / Animas
    Completed acquisition by Medtronic plc of certain assets of Animas Corporation Decision on relevant merger situation and substantial lessening of competition Please note that [] indicates figures or text which have been deleted or replaced in ranges at the request of the parties for reasons of commercial confidentiality. SUMMARY 1. On 19 December 2017 Medtronic plc (Medtronic) acquired certain assets (the Target Assets) from Animas Corporation (Animas), a subsidiary of Johnson & Johnson (J&J) (the Merger). Medtronic and the Target Assets are together referred to as the Parties. 2. The Competition and Markets Authority (CMA) notes that the Merger does not involve an extensive transfer of assets. For example, it does not provide for the transfer of any physical assets (eg insulin pumps or consumables), fixed assets (eg manufacturing facilities), intellectual property, R&D assets and information, or employees. 3. The CMA notes, however, that the customer and patient records being transferred through the Merger appear to be of significant value and that the combination of these assets with the other transferred assets appears to support a degree of ‘economic continuity’ that may enable Medtronic to carry on the business previously supported by these assets. 4. The CMA therefore believes that the Target Assets may be an enterprise, and that as a result of the Merger, the enterprises of Medtronic and the Target Assets have ceased to be distinct. 5. The share of supply test is met. The four-month period for a decision, as extended, has not yet expired. The CMA therefore believes that it is or may be the case that a relevant merger situation has been created.
    [Show full text]
  • 2016 Annual Report
    ANNUAL REPORT 2016 MARCH 2017 TO OUR SHAREHOLDERS ALEX GORSKY Chairman and Chief Executive Officer I’ve worked in the health care industry for Rather, true innovations are the result of WE ARE UNITED nearly 30 years. It’s been both an honor and collaboration. And that collaboration is AND INSPIRED a privilege to work for Johnson & Johnson, driven by a diversity of ideas, individuals BY OUR CREDO, a company that touches the lives of over and disciplines – working together toward WHICH RINGS a billion people every day, around the a common goal. AS TRUE TODAY world. As I look at today’s health care AS IT DID WHEN landscape, it’s incredibly clear that the Today, more than ever, the world needs IT WAS WRITTEN pace of change has never been greater, leaders who are committed to working MORE THAN 70 or frankly, more exciting. together to help bring improved health YEARS AGO. and wellness to every person in every Today’s rapid change brings both corner of the globe. As the world’s largest opportunities and risks for any company and most broadly based health care in health care, and we are prepared company, we are uniquely positioned to help to address both. There are significant transform global health care; to shine a light challenges to overcome, but the tools, the on the most important issues we are facing; insights, the technologies, the innovations to collaborate across boundaries and – both evolutions and revolutions – all borders; to uncover scientific insights and combine to make today one of the most ideas; and to dedicate resources towards promising times for human health and for creating tomorrow’s breakthroughs.
    [Show full text]
  • 2012 Annual Report (Essentials)
    Please visit jdrf.org/2012annualreport to view the entire Annual Report online. 2012 Annual Report (Essentials) 42 YEARS. 42 REASONS. Please visit jdrf.org/2012annualreport to view the entire Annual Report online. Table of Contents CEO Message ...........................................................3 JDRF Supporters ....................................................5 Financials ................................................................24 Leadership ..............................................................25 About JDRF JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Type 1 diabetes is an autoimmune disease that strikes both children and adults. Unrelated to diet or lifestyle, T1D causes lifelong dependence on injected or pumped insulin and carries the constant danger of life-threatening complications. It requires intensive, 24/7 management. There are no days off, and there is no cure. Parents founded JDRF in 1970 to help their children with T1D by funding research to find a cure for this poorly understood and often deadly disease. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF has grown to become the largest nongovernmental funder of T1D research. JDRF has awarded more than $1.7 billion to diabetes research since our founding. Our goal is simple: we want to create a world without T1D. JDRF is the only global organization with a strategic plan to bring a continuous stream of life-changing therapies, and ultimately, a cure for T1D. 2 Please visit jdrf.org/2012annualreport to view the entire Annual Report online. CEO Message A Vision for the Future Our 2012 Annual Report is a JDRF isn’t just imagining keeping patients healthy celebration of JDRF’s 42nd this future. We’re making it and safe until our vision is year highlighting many of happen.
    [Show full text]